Does dual trigger improve euploidy rate in normoresponder? A cross-sectional study

Area of Science:

• Reproductive Endocrinology
• In Vitro Fertilization
• Human Embryology

Background:

• Dual triggering, combining gonadotropin-releasing hormone (GnRH) analog and human chorionic gonadotropin (hCG), has shown promise for specific patient groups.
• Previous research indicated benefits for women with low mature oocyte yield or empty follicle syndrome.

Purpose of the Study:

• To evaluate the impact of dual triggering (hCG + GnRH agonist) on embryo euploidy rates.
• To determine if dual triggering improves in vitro fertilization outcomes in normoresponder women.

Main Methods:

• A cross-sectional study included 494 normoresponder women undergoing controlled ovarian stimulation.
• Participants were divided into two groups: hCG trigger (n=274) and dual trigger (hCG+GnRHa, n=220).
• Preimplantation genetic testing for aneuploidy (PGT-A) was performed on all biopsied embryos.

Main Results:

• A total of 1504 embryos were biopsied (881 in hCG group, 623 in dual trigger group).
• Euploidy rates were 35.4% in the hCG group and 29.8% in the dual trigger group.
• The hCG group showed a numerically higher euploidy rate per biopsied embryo (31.4% vs 26.5%), but the difference was not statistically significant (p > 0.05).

Conclusions:

• Adding a GnRH agonist to hCG for final follicular maturation in normoresponders does not enhance embryo euploidy rates.
• Dual triggering did not demonstrate a significant improvement in euploidy rates compared to hCG alone in this population.
• Further research may be needed to identify specific patient subgroups who benefit from dual triggering.